Index RUT
P/E -
EPS (ttm) -1.08
Insider Own 21.18%
Shs Outstand 57.82M
Perf Week 14.02%
Market Cap 839.96M
Forward P/E 83.17
EPS next Y 0.16
Insider Trans -1.82%
Shs Float 49.34M
Perf Month 0.90%
Income -61.69M
PEG -
EPS next Q -0.09
Inst Own 74.15%
Short Float 9.40%
Perf Quarter 2.84%
Sales 202.09M
P/S 4.16
EPS this Y 44.61%
Inst Trans 0.64%
Short Ratio 7.70
Perf Half Y 69.23%
Book/sh -0.36
P/B -
EPS next Y 146.54%
ROA -33.62%
Short Interest 4.64M
Perf Year 57.88%
Cash/sh 1.00
P/C 13.37
EPS next 5Y 16.50%
ROE -1279.29%
52W Range 7.07 - 15.43
Perf YTD 27.45%
Dividend Est. -
P/FCF -
EPS past 5Y 10.81%
ROI -59.04%
52W High -13.04%
Beta 1.32
Dividend TTM -
Quick Ratio 2.10
Sales past 5Y 44.65%
Gross Margin 67.00%
52W Low 89.82%
ATR (14) 0.46
Dividend Ex-Date -
Current Ratio 2.33
EPS Y/Y TTM 18.34%
Oper. Margin -17.87%
RSI (14) 64.83
Volatility 4.13% 3.46%
Employees 273
Debt/Eq -
Sales Y/Y TTM 35.98%
Profit Margin -30.52%
Recom 1.12
Target Price 22.29
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 11.67%
Payout -
Rel Volume 0.95
Prev Close 13.39
Sales Surprise 3.61%
EPS Surprise 45.49%
Sales Q/Q 39.76%
Earnings May 07 AMC
Avg Volume 602.24K
Price 13.42
SMA20 10.30%
SMA50 0.93%
SMA200 24.83%
Trades
Volume 570,993
Change 0.22%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-29-24 Upgrade
Barclays
Equal Weight → Overweight
$10 → $16
Jun-23-22 Initiated
Needham
Buy
$18
May-12-22 Upgrade
Barclays
Underweight → Equal Weight
$8 → $10
Jan-20-22 Upgrade
Truist
Hold → Buy
$11
May-06-21 Upgrade
Mizuho
Neutral → Buy
$15
Apr-08-21 Reiterated
H.C. Wainwright
Buy
$20 → $22
Feb-24-21 Downgrade
Truist
Buy → Hold
$12
Jul-07-20 Downgrade
Mizuho
Buy → Neutral
$8 → $3
Feb-06-20 Resumed
Mizuho
Buy
Nov-26-19 Initiated
SVB Leerink
Outperform
$25
Sep-05-19 Resumed
Mizuho
Buy
$30
Jun-28-19 Initiated
Wells Fargo
Market Perform
$16
Jun-11-19 Initiated
Barclays
Underweight
$13
Mar-20-19 Initiated
SunTrust
Buy
$30
Feb-14-19 Initiated
H.C. Wainwright
Buy
$37
Jan-29-19 Initiated
Stifel
Buy
$27
Show Previous Ratings
Today 06:35PM
05:46PM
04:05PM
May-02-24 07:37AM
Apr-23-24 04:30PM
10:39AM
Loading…
Apr-21-24 10:39AM
Apr-17-24 04:05PM
Apr-12-24 04:05PM
Mar-26-24 08:00AM
Mar-14-24 07:04AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Mar-08-24 04:05PM
03:24PM
12:30PM
(Thomson Reuters StreetEvents)
10:34PM
Loading…
Mar-07-24 10:34PM
09:53PM
04:05PM
Mar-04-24 08:28PM
Mar-01-24 08:30AM
Feb-27-24 08:30AM
Feb-22-24 04:30PM
Feb-09-24 04:05PM
Feb-02-24 09:10PM
Jan-16-24 05:28PM
Jan-12-24 04:23PM
Jan-09-24 06:21PM
Jan-04-24 04:05PM
Dec-20-23 08:00AM
Dec-08-23 04:30PM
09:08AM
Loading…
Nov-13-23 09:08AM
Nov-10-23 05:16PM
Nov-07-23 04:16PM
Nov-06-23 08:45AM
Nov-01-23 08:45AM
Oct-25-23 08:45AM
08:45AM
Oct-08-23 06:41PM
Sep-29-23 04:05PM
Sep-13-23 04:10PM
Sep-09-23 01:03PM
Sep-03-23 05:29AM
Aug-29-23 08:45AM
Aug-27-23 07:20PM
Aug-23-23 06:53PM
Aug-21-23 08:45AM
Aug-08-23 09:15AM
08:45AM
Aug-02-23 05:45PM
04:05PM
Jul-27-23 11:42AM
08:45AM
Jul-26-23 10:02AM
08:45AM
Jul-19-23 08:45AM
Jul-15-23 07:30AM
Jun-29-23 09:00AM
Jun-22-23 08:45AM
Jun-08-23 04:05PM
Jun-02-23 06:38AM
May-16-23 01:44PM
May-09-23 05:25PM
04:01PM
04:01PM
May-05-23 01:37PM
Apr-17-23 11:05AM
Apr-04-23 10:39AM
Mar-11-23 06:38AM
Mar-09-23 10:12AM
(Thomson Reuters StreetEvents)
Mar-08-23 05:35PM
04:05PM
Feb-28-23 08:45AM
Feb-27-23 08:45AM
Feb-22-23 08:45AM
Feb-10-23 11:07AM
Jan-31-23 08:45AM
Jan-30-23 12:02PM
07:09AM
Jan-28-23 08:00AM
Jan-23-23 09:00AM
08:00AM
Jan-20-23 01:54PM
Jan-19-23 01:15PM
Jan-18-23 08:45AM
Jan-03-23 10:03AM
Dec-08-22 08:45AM
Dec-07-22 10:00AM
09:17AM
Nov-10-22 05:57AM
Nov-08-22 06:25PM
04:05PM
Nov-02-22 08:45AM
Oct-25-22 08:45AM
Oct-04-22 08:20AM
Sep-21-22 08:45AM
Sep-20-22 09:03AM
Sep-18-22 07:30AM
Sep-09-22 02:30PM
Sep-06-22 04:05PM
Aug-30-22 08:15AM
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MOATAZEDI DAVID See Remarks Mar 27 '24 Sale 13.86 6,236 86,431 689,614 Mar 29 07:08 PM MOATAZEDI DAVID See Remarks Mar 19 '24 Sale 13.92 96,566 1,344,604 695,850 Mar 21 06:08 PM Avelar Rui See Remarks Mar 19 '24 Sale 13.92 27,603 384,350 372,288 Mar 21 06:09 PM Beaver Sandra Chief Financial Officer Mar 19 '24 Sale 13.92 5,672 78,978 154,201 Mar 21 06:09 PM MOATAZEDI DAVID See Remarks Feb 22 '24 Sale 13.08 7,706 100,804 792,416 Feb 23 08:27 PM Beaver Sandra Chief Financial Officer Feb 22 '24 Sale 13.08 1,821 23,821 159,873 Feb 23 08:27 PM Avelar Rui See Remarks Feb 22 '24 Sale 13.08 1,821 23,821 399,891 Feb 23 08:27 PM Parschauer Karah Herdman Director Jan 30 '24 Sale 13.14 11,931 156,733 31,243 Feb 02 04:57 PM MOATAZEDI DAVID See Remarks Dec 08 '23 Sale 9.73 31,300 304,505 603,944 Dec 08 06:15 PM MOATAZEDI DAVID See Remarks Dec 06 '23 Sale 10.09 51,348 517,891 635,244 Dec 08 06:15 PM Medytox Inc. Former 10% Owner Oct 16 '23 Sale 7.50 1,690,663 12,679,972 3,381,326 Oct 18 04:21 PM Beaver Sandra Chief Financial Officer Sep 06 '23 Sale 9.70 3,178 30,827 113,368 Sep 08 08:54 PM MOATAZEDI DAVID See Remarks Aug 16 '23 Sale 10.27 14,778 151,770 686,592 Aug 16 08:25 PM Beaver Sandra Chief Financial Officer Aug 16 '23 Sale 10.27 2,211 22,707 116,546 Aug 16 08:25 PM Avelar Rui See Remarks Aug 16 '23 Sale 10.27 2,211 22,707 353,386 Aug 16 08:25 PM Malik Vikram Director Aug 15 '23 Buy 7.41 174,967 1,296,505 275,550 Aug 15 04:34 PM
Index RUT
P/E -
EPS (ttm) -0.49
Insider Own 24.37%
Shs Outstand 43.67M
Perf Week 13.15%
Market Cap 755.00M
Forward P/E -
EPS next Y -0.28
Insider Trans 2.40%
Shs Float 33.18M
Perf Month 19.10%
Income -21.43M
PEG -
EPS next Q -0.11
Inst Own 53.45%
Short Float 7.02%
Perf Quarter 26.64%
Sales 84.82M
P/S 8.90
EPS this Y 5.44%
Inst Trans -3.47%
Short Ratio 6.31
Perf Half Y 214.63%
Book/sh 2.31
P/B 7.44
EPS next Y 40.05%
ROA -15.91%
Short Interest 2.33M
Perf Year 149.06%
Cash/sh 1.79
P/C 9.60
EPS next 5Y -
ROE -20.39%
52W Range 4.60 - 20.90
Perf YTD 152.35%
Dividend Est. -
P/FCF -
EPS past 5Y 20.06%
ROI -21.11%
52W High -17.66%
Beta 0.75
Dividend TTM -
Quick Ratio 5.27
Sales past 5Y 37.03%
Gross Margin 86.54%
52W Low 274.13%
ATR (14) 0.91
Dividend Ex-Date -
Current Ratio 5.52
EPS Y/Y TTM 77.54%
Oper. Margin -30.27%
RSI (14) 65.54
Volatility 5.67% 5.64%
Employees 100
Debt/Eq 0.01
Sales Y/Y TTM 29.96%
Profit Margin -25.26%
Recom 1.86
Target Price 21.43
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q -187.26%
Payout -
Rel Volume 1.05
Prev Close 17.24
Sales Surprise -12.50%
EPS Surprise -10.29%
Sales Q/Q -25.71%
Earnings May 07 AMC
Avg Volume 368.82K
Price 17.21
SMA20 12.36%
SMA50 9.38%
SMA200 85.12%
Trades
Volume 386,559
Change -0.17%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-23 Upgrade
Wedbush
Neutral → Outperform
$5 → $13
Apr-03-23 Downgrade
Guggenheim
Buy → Neutral
Jan-27-23 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$4
Jan-05-23 Downgrade
Cowen
Outperform → Market Perform
Dec-02-22 Downgrade
BofA Securities
Buy → Neutral
$23 → $5
Dec-02-22 Downgrade
BofA Securities
Buy → Neutral
Oct-31-22 Downgrade
Wedbush
Outperform → Neutral
$6
Oct-31-22 Downgrade
JP Morgan
Neutral → Underweight
$16 → $7
Jul-06-22 Resumed
Canaccord Genuity
Buy
$35
Jun-24-22 Initiated
BMO Capital Markets
Outperform
$27
Feb-03-22 Resumed
Guggenheim
Buy
$22
Nov-19-21 Resumed
Morgan Stanley
Equal-Weight
$25
Nov-16-21 Downgrade
JP Morgan
Overweight → Neutral
$57 → $30
May-07-21 Upgrade
BofA Securities
Neutral → Buy
Apr-23-21 Resumed
Cowen
Outperform
Mar-22-21 Resumed
JP Morgan
Overweight
$57 → $52
Jan-15-21 Downgrade
BofA Securities
Buy → Neutral
$56
Nov-09-20 Reiterated
H.C. Wainwright
Buy
$52 → $65
May-05-20 Initiated
Barclays
Overweight
$44
May-01-20 Initiated
Janney
Buy
Show Previous Ratings
Today 06:12PM
05:55PM
04:05PM
Apr-26-24 07:05AM
Apr-25-24 04:05PM
09:55AM
Loading…
Mar-28-24 09:55AM
Mar-20-24 07:37AM
Mar-14-24 09:05AM
Mar-12-24 09:55AM
Mar-05-24 12:00PM
Mar-04-24 08:45AM
07:30AM
Mar-01-24 09:42PM
(Thomson Reuters StreetEvents) +11.92%
Feb-29-24 05:25PM
04:37PM
04:05PM
Loading…
04:05PM
Feb-22-24 10:00AM
Feb-16-24 07:30AM
Feb-13-24 04:10AM
Jan-02-24 04:05PM
Dec-13-23 04:05PM
Dec-12-23 01:05AM
Dec-03-23 03:04AM
Nov-30-23 11:04PM
Nov-15-23 01:14PM
01:33AM
(Thomson Reuters StreetEvents)
Nov-13-23 05:31PM
05:25PM
04:05PM
Nov-08-23 12:00PM
07:05AM
Loading…
Oct-31-23 07:05AM
Oct-18-23 04:05PM
Oct-17-23 04:05PM
Oct-16-23 04:05PM
Sep-21-23 04:05PM
Sep-06-23 04:05PM
Aug-23-23 09:55AM
Aug-13-23 06:25AM
Aug-10-23 05:15PM
04:05PM
Aug-02-23 04:05PM
Aug-01-23 04:05PM
Jul-26-23 12:35PM
Jun-02-23 03:15PM
May-26-23 09:00AM
09:00AM
May-23-23 09:00AM
May-18-23 06:39AM
May-13-23 08:18AM
May-10-23 06:14AM
02:52AM
(Thomson Reuters StreetEvents)
May-08-23 05:15PM
04:01PM
May-01-23 10:01AM
Apr-28-23 09:00AM
Apr-18-23 09:00AM
Apr-17-23 10:57AM
Apr-05-23 07:44PM
09:55AM
09:00AM
Apr-04-23 05:12AM
Mar-30-23 05:25PM
04:01PM
02:42PM
Mar-21-23 04:01PM
Mar-15-23 10:22AM
Feb-20-23 10:00AM
Feb-16-23 10:01AM
07:57AM
Feb-02-23 09:00AM
Jan-05-23 10:34AM
Jan-04-23 04:01PM
Jan-03-23 09:00AM
Dec-21-22 09:00AM
Dec-16-22 04:01PM
Dec-14-22 09:00AM
Dec-08-22 09:00AM
Dec-07-22 09:19AM
Dec-06-22 09:00AM
Dec-01-22 05:34PM
Nov-07-22 05:15PM
04:01PM
Nov-02-22 04:01PM
Oct-31-22 03:01PM
08:52AM
05:34AM
Oct-28-22 03:33PM
Oct-06-22 09:34AM
Oct-03-22 09:00AM
Sep-29-22 02:53AM
Sep-26-22 09:00AM
Sep-09-22 08:35AM
Sep-01-22 04:05PM
Aug-30-22 09:00AM
Aug-13-22 08:29AM
Aug-08-22 05:45PM
04:05PM
Aug-02-22 09:00AM
Jul-12-22 09:00AM
Jun-30-22 07:31AM
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gad Thomas CHIEF BUSINESS OFFICER Mar 05 '24 Sale 16.44 3,900 64,116 158,700 Mar 07 05:01 PM Rajah Vignesh SVP & CHIEF MEDICAL OFFICER Mar 05 '24 Sale 16.53 1,711 28,283 33,889 Mar 07 05:02 PM Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER Mar 05 '24 Sale 16.55 1,682 27,837 33,918 Mar 07 04:59 PM Gad Thomas Chief Business Officer Dec 21 '23 Option Exercise 2.00 50,000 100,000 140,500 Dec 26 04:15 PM Gad Thomas Chief Business Officer Dec 15 '23 Sale 6.61 50,000 330,500 265,032 Dec 15 07:40 PM Gad Thomas Chief Business Officer Dec 14 '23 Sale 6.83 50,000 341,500 315,032 Dec 15 07:40 PM Gad Thomas Chief Business Officer Dec 13 '23 Sale 6.58 50,000 329,000 365,032 Dec 15 07:40 PM Wedell-Wedellsborg Johan Director Dec 11 '23 Buy 7.01 102,863 720,843 4,552,778 Dec 11 05:25 PM WG Biotech ApS Director Dec 11 '23 Buy 7.01 102,863 720,843 4,552,778 Dec 11 05:25 PM Wedell-Wedellsborg Johan Director Dec 11 '23 Buy 6.85 6,455 44,232 4,559,233 Dec 12 08:26 AM WG Biotech ApS Director Dec 11 '23 Buy 6.85 6,455 44,232 4,559,233 Dec 12 08:27 AM WG Biotech ApS Director Dec 08 '23 Buy 6.99 18,503 129,379 4,449,915 Dec 11 05:25 PM Wedell-Wedellsborg Johan Director Dec 08 '23 Buy 6.99 18,503 129,379 4,449,915 Dec 11 05:25 PM Wedell-Wedellsborg Johan Director Dec 07 '23 Buy 6.50 6,183 40,190 4,431,412 Dec 11 05:25 PM WG Biotech ApS Director Dec 07 '23 Buy 6.50 6,183 40,190 4,431,412 Dec 11 05:25 PM Wedell-Wedellsborg Johan Director Nov 29 '23 Buy 5.97 51,837 309,477 4,425,229 Dec 01 05:14 PM WG Biotech ApS Director Nov 29 '23 Buy 5.97 51,837 309,477 4,425,229 Dec 01 05:15 PM Wedell-Wedellsborg Johan Director Nov 28 '23 Buy 5.81 30,671 178,275 4,373,392 Nov 29 05:15 PM WG Biotech ApS Director Nov 28 '23 Buy 5.81 30,671 178,275 4,373,392 Nov 29 05:14 PM WG Biotech ApS Director Nov 27 '23 Buy 5.49 62,516 343,019 4,342,721 Nov 29 05:14 PM Wedell-Wedellsborg Johan Director Nov 27 '23 Buy 5.49 62,516 343,019 4,342,721 Nov 29 05:15 PM Gad Thomas Chief Business Officer Nov 21 '23 Sale 5.31 75,000 397,988 415,032 Nov 22 05:00 PM Gad Thomas Chief Business Officer Nov 20 '23 Sale 5.30 75,000 397,395 490,032 Nov 22 05:00 PM Wedell-Wedellsborg Johan Director May 15 '23 Buy 9.65 101,740 981,404 4,280,205 May 17 05:07 PM WG Biotech ApS Director May 15 '23 Buy 9.65 101,740 981,404 4,280,205 May 17 05:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite